Dashboard
1
High Management Efficiency with a high ROE of 11.75%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 9.23
3
High Debt company with Weak Long Term Fundamental Strength
4
Flat results in Dec 15
5
With ROE of 7.53%, it has a Fair valuation with a 0.10 Price to Book Value
6
Underperformed the market in the last 1 year
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.32%
0%
0.32%
6 Months
2.7%
0%
2.7%
1 Year
1.58%
0%
1.58%
2 Years
-8.35%
0%
-8.35%
3 Years
-27.15%
0%
-27.15%
4 Years
-2.76%
0%
-2.76%
5 Years
-0.48%
0%
-0.48%
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.06%
EBIT Growth (5y)
-0.25%
EBIT to Interest (avg)
9.23
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.57
Tax Ratio
16.19%
Dividend Payout Ratio
46.45%
Pledged Shares
0
Institutional Holding
0.14%
ROCE (avg)
15.88%
ROE (avg)
11.75%
Valuation key factors
Factor
Value
P/E Ratio
1
Industry P/E
Price to Book Value
0.10
EV to EBIT
0.86
EV to EBITDA
0.65
EV to Capital Employed
0.07
EV to Sales
0.03
PEG Ratio
NA
Dividend Yield
4.77%
ROCE (Latest)
7.89%
ROE (Latest)
7.53%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
20,808.20
19,462.00
6.92%
Operating Profit (PBDIT) excl Other Income
1,051.40
951.30
10.52%
Interest
110.50
115.40
-4.25%
Exceptional Items
-2.00
-8.40
76.19%
Consolidate Net Profit
775.30
686.90
12.87%
Operating Profit Margin (Excl OI)
38.10%
35.50%
0.26%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 6.92% vs -4.59% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 12.87% vs -35.43% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
80,987.30
83,064.10
-2.50%
Operating Profit (PBDIT) excl Other Income
4,645.10
6,006.60
-22.67%
Interest
476.40
519.50
-8.30%
Exceptional Items
-377.60
44.50
-948.54%
Consolidate Net Profit
3,253.50
4,706.50
-30.87%
Operating Profit Margin (Excl OI)
44.80%
59.20%
-1.44%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -2.50% vs 1.33% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -30.87% vs -4.85% in Dec 2023
About Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. 
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






